Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

Meanwhile — in a late-breaking moment — federal officials are having to pivot on the fly after insurers panned the effort to ...

The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from ...

The federal government scrapped a plan to have health insurance companies fund coverage of obesity drugs for seniors, opting instead to pay for the medicine with taxpayer dollars through the ...

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...

Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for ...

Eli Lilly (LLY) stock and Novo Nordisk (NONOF) stock are in focus as Medicare extends interim coverage for GLP-1 weight loss ...

Medicare's GLP-1 bridge program launches July 1 with a $50 monthly copay after major insurers rejected the original BALANCE ...

Insurance coverage for GLP-1 medications like Ozempic and Wegovy varies widely depending on the condition and your plan.

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech ...

Retailers race into GLP-1 market as Amazon and Walmart expand weight management programs, reshaping access and care delivery in obesity treatment.

UnitedHealth Group Inc. sees difficulties with the Trump administration’s plan to cover obesity drugs in Medicare next year, ...